Artwork
iconShare
 
Manage episode 512860611 series 2864794
Content provided by Biotech Connection Los Angeles, Gabriella Rubert, Daniel Arce, Katherine Merkling, Serena Gao, Bryan Jimenez, Danielle Luu, and Stephanie Wu. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Biotech Connection Los Angeles, Gabriella Rubert, Daniel Arce, Katherine Merkling, Serena Gao, Bryan Jimenez, Danielle Luu, and Stephanie Wu or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://staging.podcastplayer.com/legal.

CEO of Vistagen, Shawn Singh, returns to Inside Biotech to discuss groundbreaking developments in intranasal therapeutics. Shawn shares exciting results from Vistagen’s fast-track phase 3 trials, explains how intranasal drug delivery bypasses limitations of traditional therapeutics relying on systemic absorption, and reflects on telehealth’s role in accessibility. This conversation spotlights a transformative moment in neuroscience, drug development and mental health innovation.

Learn more about Vistagen: https://www.vistagen.com/
Listen to our previous episode with Shawn to learn more about social anxiety disorder and the earlier days of Vistagen: https://inside-biotech.simplecast.com/episodes/shawn-singh-ceo-of-vistagen-mental-health-biopharmaceuticals

Follow our Instagram @insidebiotech for updates about episodes and upcoming guests!

To learn more about BCLA’s events and consulting visit our website.

Follow BCLA on LinkedIn

  continue reading

36 episodes